0000318154false2020Q312/3100003181542020-01-012020-09-300000318154us-gaap:CommonStockMemberexch:XNGS2020-01-012020-09-300000318154amgn:A1.250SeniorNotesDue2022Memberexch:XNYS2020-01-012020-09-300000318154amgn:A2.00SeniorNotesDue2026Memberexch:XNYS2020-01-012020-09-30xbrli:shares00003181542020-10-23iso4217:USD0000318154us-gaap:ProductMember2020-07-012020-09-300000318154us-gaap:ProductMember2019-07-012019-09-300000318154us-gaap:ProductMember2020-01-012020-09-300000318154us-gaap:ProductMember2019-01-012019-09-300000318154us-gaap:ProductAndServiceOtherMember2020-07-012020-09-300000318154us-gaap:ProductAndServiceOtherMember2019-07-012019-09-300000318154us-gaap:ProductAndServiceOtherMember2020-01-012020-09-300000318154us-gaap:ProductAndServiceOtherMember2019-01-012019-09-3000003181542020-07-012020-09-3000003181542019-07-012019-09-3000003181542019-01-012019-09-30iso4217:USDxbrli:shares00003181542020-09-3000003181542019-12-310000318154us-gaap:CommonStockMember2019-12-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-12-310000318154us-gaap:RetainedEarningsMember2019-12-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000318154us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000318154srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000318154us-gaap:RetainedEarningsMember2020-01-012020-03-3100003181542020-01-012020-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000318154us-gaap:CommonStockMember2020-01-012020-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-01-012020-03-310000318154us-gaap:CommonStockMember2020-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-03-310000318154us-gaap:RetainedEarningsMember2020-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100003181542020-03-310000318154us-gaap:RetainedEarningsMember2020-04-012020-06-3000003181542020-04-012020-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300000318154us-gaap:CommonStockMember2020-04-012020-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-04-012020-06-300000318154us-gaap:CommonStockMember2020-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-06-300000318154us-gaap:RetainedEarningsMember2020-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000003181542020-06-300000318154us-gaap:RetainedEarningsMember2020-07-012020-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000318154us-gaap:CommonStockMember2020-07-012020-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-07-012020-09-300000318154us-gaap:CommonStockMember2020-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-09-300000318154us-gaap:RetainedEarningsMember2020-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000318154us-gaap:CommonStockMember2018-12-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2018-12-310000318154us-gaap:RetainedEarningsMember2018-12-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-3100003181542018-12-310000318154us-gaap:RetainedEarningsMember2019-01-012019-03-3100003181542019-01-012019-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310000318154us-gaap:CommonStockMember2019-01-012019-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-01-012019-03-310000318154us-gaap:CommonStockMember2019-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-03-310000318154us-gaap:RetainedEarningsMember2019-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-3100003181542019-03-310000318154us-gaap:RetainedEarningsMember2019-04-012019-06-3000003181542019-04-012019-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300000318154us-gaap:CommonStockMember2019-04-012019-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-04-012019-06-300000318154us-gaap:CommonStockMember2019-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-06-300000318154us-gaap:RetainedEarningsMember2019-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-3000003181542019-06-300000318154us-gaap:RetainedEarningsMember2019-07-012019-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000318154us-gaap:CommonStockMember2019-07-012019-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-07-012019-09-300000318154us-gaap:CommonStockMember2019-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-09-300000318154us-gaap:RetainedEarningsMember2019-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-3000003181542019-09-30amgn:segment0000318154amgn:EnbrelMembercountry:US2020-07-012020-09-300000318154amgn:EnbrelMemberus-gaap:NonUsMember2020-07-012020-09-300000318154amgn:EnbrelMember2020-07-012020-09-300000318154amgn:EnbrelMembercountry:US2019-07-012019-09-300000318154amgn:EnbrelMemberus-gaap:NonUsMember2019-07-012019-09-300000318154amgn:EnbrelMember2019-07-012019-09-300000318154amgn:ProliaMembercountry:US2020-07-012020-09-300000318154amgn:ProliaMemberus-gaap:NonUsMember2020-07-012020-09-300000318154amgn:ProliaMember2020-07-012020-09-300000318154amgn:ProliaMembercountry:US2019-07-012019-09-300000318154amgn:ProliaMemberus-gaap:NonUsMember2019-07-012019-09-300000318154amgn:ProliaMember2019-07-012019-09-300000318154country:USamgn:NeulastaMember2020-07-012020-09-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2020-07-012020-09-300000318154amgn:NeulastaMember2020-07-012020-09-300000318154country:USamgn:NeulastaMember2019-07-012019-09-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2019-07-012019-09-300000318154amgn:NeulastaMember2019-07-012019-09-300000318154amgn:OtezlaMembercountry:US2020-07-012020-09-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2020-07-012020-09-300000318154amgn:OtezlaMember2020-07-012020-09-300000318154amgn:OtezlaMembercountry:US2019-07-012019-09-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2019-07-012019-09-300000318154amgn:OtezlaMember2019-07-012019-09-300000318154amgn:XgevaMembercountry:US2020-07-012020-09-300000318154amgn:XgevaMemberus-gaap:NonUsMember2020-07-012020-09-300000318154amgn:XgevaMember2020-07-012020-09-300000318154amgn:XgevaMembercountry:US2019-07-012019-09-300000318154amgn:XgevaMemberus-gaap:NonUsMember2019-07-012019-09-300000318154amgn:XgevaMember2019-07-012019-09-300000318154country:USamgn:AranespMember2020-07-012020-09-300000318154amgn:AranespMemberus-gaap:NonUsMember2020-07-012020-09-300000318154amgn:AranespMember2020-07-012020-09-300000318154country:USamgn:AranespMember2019-07-012019-09-300000318154amgn:AranespMemberus-gaap:NonUsMember2019-07-012019-09-300000318154amgn:AranespMember2019-07-012019-09-300000318154amgn:KyprolisMembercountry:US2020-07-012020-09-300000318154amgn:KyprolisMemberus-gaap:NonUsMember2020-07-012020-09-300000318154amgn:KyprolisMember2020-07-012020-09-300000318154amgn:KyprolisMembercountry:US2019-07-012019-09-300000318154amgn:KyprolisMemberus-gaap:NonUsMember2019-07-012019-09-300000318154amgn:KyprolisMember2019-07-012019-09-300000318154amgn:RepathaevolocumabMembercountry:US2020-07-012020-09-300000318154amgn:RepathaevolocumabMemberus-gaap:NonUsMember2020-07-012020-09-300000318154amgn:RepathaevolocumabMember2020-07-012020-09-300000318154amgn:RepathaevolocumabMembercountry:US2019-07-012019-09-300000318154amgn:RepathaevolocumabMemberus-gaap:NonUsMember2019-07-012019-09-300000318154amgn:RepathaevolocumabMember2019-07-012019-09-300000318154country:USamgn:OtherProductsMember2020-07-012020-09-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2020-07-012020-09-300000318154amgn:OtherProductsMember2020-07-012020-09-300000318154country:USamgn:OtherProductsMember2019-07-012019-09-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2019-07-012019-09-300000318154amgn:OtherProductsMember2019-07-012019-09-300000318154us-gaap:ProductMembercountry:US2020-07-012020-09-300000318154us-gaap:ProductMemberus-gaap:NonUsMember2020-07-012020-09-300000318154us-gaap:ProductMembercountry:US2019-07-012019-09-300000318154us-gaap:ProductMemberus-gaap:NonUsMember2019-07-012019-09-300000318154amgn:EnbrelMembercountry:US2020-01-012020-09-300000318154amgn:EnbrelMemberus-gaap:NonUsMember2020-01-012020-09-300000318154amgn:EnbrelMember2020-01-012020-09-300000318154amgn:EnbrelMembercountry:US2019-01-012019-09-300000318154amgn:EnbrelMemberus-gaap:NonUsMember2019-01-012019-09-300000318154amgn:EnbrelMember2019-01-012019-09-300000318154amgn:ProliaMembercountry:US2020-01-012020-09-300000318154amgn:ProliaMemberus-gaap:NonUsMember2020-01-012020-09-300000318154amgn:ProliaMember2020-01-012020-09-300000318154amgn:ProliaMembercountry:US2019-01-012019-09-300000318154amgn:ProliaMemberus-gaap:NonUsMember2019-01-012019-09-300000318154amgn:ProliaMember2019-01-012019-09-300000318154country:USamgn:NeulastaMember2020-01-012020-09-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2020-01-012020-09-300000318154amgn:NeulastaMember2020-01-012020-09-300000318154country:USamgn:NeulastaMember2019-01-012019-09-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2019-01-012019-09-300000318154amgn:NeulastaMember2019-01-012019-09-300000318154amgn:OtezlaMembercountry:US2020-01-012020-09-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2020-01-012020-09-300000318154amgn:OtezlaMember2020-01-012020-09-300000318154amgn:OtezlaMembercountry:US2019-01-012019-09-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2019-01-012019-09-300000318154amgn:OtezlaMember2019-01-012019-09-300000318154amgn:XgevaMembercountry:US2020-01-012020-09-300000318154amgn:XgevaMemberus-gaap:NonUsMember2020-01-012020-09-300000318154amgn:XgevaMember2020-01-012020-09-300000318154amgn:XgevaMembercountry:US2019-01-012019-09-300000318154amgn:XgevaMemberus-gaap:NonUsMember2019-01-012019-09-300000318154amgn:XgevaMember2019-01-012019-09-300000318154country:USamgn:AranespMember2020-01-012020-09-300000318154amgn:AranespMemberus-gaap:NonUsMember2020-01-012020-09-300000318154amgn:AranespMember2020-01-012020-09-300000318154country:USamgn:AranespMember2019-01-012019-09-300000318154amgn:AranespMemberus-gaap:NonUsMember2019-01-012019-09-300000318154amgn:AranespMember2019-01-012019-09-300000318154amgn:KyprolisMembercountry:US2020-01-012020-09-300000318154amgn:KyprolisMemberus-gaap:NonUsMember2020-01-012020-09-300000318154amgn:KyprolisMember2020-01-012020-09-300000318154amgn:KyprolisMembercountry:US2019-01-012019-09-300000318154amgn:KyprolisMemberus-gaap:NonUsMember2019-01-012019-09-300000318154amgn:KyprolisMember2019-01-012019-09-300000318154amgn:RepathaevolocumabMembercountry:US2020-01-012020-09-300000318154amgn:RepathaevolocumabMemberus-gaap:NonUsMember2020-01-012020-09-300000318154amgn:RepathaevolocumabMember2020-01-012020-09-300000318154amgn:RepathaevolocumabMembercountry:US2019-01-012019-09-300000318154amgn:RepathaevolocumabMemberus-gaap:NonUsMember2019-01-012019-09-300000318154amgn:RepathaevolocumabMember2019-01-012019-09-300000318154country:USamgn:OtherProductsMember2020-01-012020-09-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2020-01-012020-09-300000318154amgn:OtherProductsMember2020-01-012020-09-300000318154country:USamgn:OtherProductsMember2019-01-012019-09-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2019-01-012019-09-300000318154amgn:OtherProductsMember2019-01-012019-09-300000318154us-gaap:ProductMembercountry:US2020-01-012020-09-300000318154us-gaap:ProductMemberus-gaap:NonUsMember2020-01-012020-09-300000318154us-gaap:ProductMembercountry:US2019-01-012019-09-300000318154us-gaap:ProductMemberus-gaap:NonUsMember2019-01-012019-09-30xbrli:pure0000318154amgn:BeiGeneMember2020-01-022020-01-020000318154us-gaap:ResearchAndDevelopmentExpenseMemberamgn:BeiGeneMember2020-07-012020-09-300000318154us-gaap:ResearchAndDevelopmentExpenseMemberamgn:BeiGeneMember2020-01-012020-09-300000318154us-gaap:OtherCurrentAssetsMemberamgn:BeiGeneMember2020-09-300000318154us-gaap:USTreasurySecuritiesMember2020-09-300000318154us-gaap:USTreasuryBillSecuritiesMember2020-09-300000318154amgn:CorporateDebtSecuritiesFinancialMember2020-09-300000318154amgn:CorporateDebtSecuritiesIndustrialMember2020-09-300000318154amgn:CorporateDebtSecuritiesOtherMember2020-09-300000318154us-gaap:ResidentialMortgageBackedSecuritiesMember2020-09-300000318154us-gaap:MoneyMarketFundsMember2020-09-300000318154amgn:OtherShortTermInterestBearingSecuritiesMember2020-09-300000318154us-gaap:USTreasurySecuritiesMember2019-12-310000318154us-gaap:USTreasuryBillSecuritiesMember2019-12-310000318154amgn:CorporateDebtSecuritiesFinancialMember2019-12-310000318154amgn:CorporateDebtSecuritiesIndustrialMember2019-12-310000318154amgn:CorporateDebtSecuritiesOtherMember2019-12-310000318154us-gaap:ResidentialMortgageBackedSecuritiesMember2019-12-310000318154us-gaap:MoneyMarketFundsMember2019-12-310000318154amgn:OtherShortTermInterestBearingSecuritiesMember2019-12-310000318154amgn:AvailableForSalesInvestmentsMember2020-09-300000318154amgn:AvailableForSalesInvestmentsMember2019-12-310000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-09-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-07-012020-09-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-07-012019-09-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-01-012020-09-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-01-012019-09-300000318154amgn:BeiGeneMember2020-01-020000318154srt:MinimumMemberamgn:BeiGeneMember2020-01-012020-09-300000318154amgn:BeiGeneMembersrt:MaximumMember2020-01-012020-09-300000318154amgn:BeiGeneMember2020-01-012020-09-300000318154amgn:BeiGeneMember2020-07-012020-09-300000318154amgn:BeiGeneMember2020-09-300000318154us-gaap:DevelopedTechnologyRightsMember2020-09-300000318154us-gaap:DevelopedTechnologyRightsMember2019-12-310000318154us-gaap:LicensingAgreementsMember2020-09-300000318154us-gaap:LicensingAgreementsMember2019-12-310000318154us-gaap:MarketingRelatedIntangibleAssetsMember2020-09-300000318154us-gaap:MarketingRelatedIntangibleAssetsMember2019-12-310000318154amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember2020-09-300000318154amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember2019-12-310000318154us-gaap:InProcessResearchAndDevelopmentMember2020-09-300000318154us-gaap:InProcessResearchAndDevelopmentMember2019-12-310000318154amgn:FourPointFiveZeroPercentNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FourPointFiveZeroPercentNotesDue2020Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FloatingRateNotesDue2020Member2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FloatingRateNotesDue2020Member2019-12-310000318154amgn:TwoPointTwoZeroNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:TwoPointTwoZeroNotesDue2020Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:ThreePointFourFivePercentNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:ThreePointFourFivePercentNotesDue2020Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointOneZeroPercentNotesDue2021Member2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointOneZeroPercentNotesDue2021Member2019-12-310000318154amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2019-12-310000318154amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMemberus-gaap:NotesPayableToBanksMember2020-09-30iso4217:EUR0000318154amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember2019-12-310000318154amgn:TwoPointSixFiveNotesDue2022Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:TwoPointSixFiveNotesDue2022Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2022Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2022Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMemberus-gaap:NotesPayableToBanksMember2020-09-30iso4217:CHF0000318154amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember2019-12-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member2020-09-30iso4217:GBP0000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member2019-12-310000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointTwoZeroNotesDue2027Member2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointTwoZeroNotesDue2027Member2019-12-310000318154amgn:FourPercentPoundSterlingNotesDue2029Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FourPercentPoundSterlingNotesDue2029Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:SixPointThreeSevenFivePercentNotesDue2037Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:SixPointThreeSevenFivePercentNotesDue2037Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:SixPointNineZeroPercentNotesDue2038Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:SixPointNineZeroPercentNotesDue2038Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:SixPointFourZeroPercentNotesDue2039Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:SixPointFourZeroPercentNotesDue2039Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneFivePercentNotesDue2040Member2020-09-300000318154amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:FourPointNineFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FourPointNineFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:FivePointOneFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FivePointOneFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSixFivePercentNotesDue2042Member2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSixFivePercentNotesDue2042Member2019-12-310000318154amgn:FivePointThreeSevenFivePercentNotesDue2043Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FivePointThreeSevenFivePercentNotesDue2043Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointThreeSevenFivePercentNotesDue2050Member2020-09-300000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember2020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember2019-12-310000318154amgn:OtherNotesDue2097Memberus-gaap:NotesPayableToBanksMember2020-09-300000318154amgn:OtherNotesDue2097Memberus-gaap:NotesPayableToBanksMember2019-12-310000318154us-gaap:NotesPayableToBanksMember2020-02-290000318154amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2020-02-290000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2020-02-290000318154amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember2020-02-290000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneFivePercentNotesDue2040Member2020-02-290000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointThreeSevenFivePercentNotesDue2050Member2020-02-290000318154us-gaap:NotesPayableToBanksMember2020-05-310000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2020-05-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneFivePercentNotesDue2040Member2020-05-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointThreeSevenFivePercentNotesDue2050Member2020-05-310000318154amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember2020-05-310000318154amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:FourPointNineFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:ThreePointFourFivePercentNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2022Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointOneZeroPercentNotesDue2021Member2020-01-012020-09-300000318154amgn:FivePointOneFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSixFivePercentNotesDue2042Member2020-01-012020-09-300000318154amgn:SixPointNineZeroPercentNotesDue2038Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:FivePointThreeSevenFivePercentNotesDue2043Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember2020-01-012020-09-300000318154amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member2020-01-012020-09-300000318154amgn:SixPointThreeSevenFivePercentNotesDue2037Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:TwoPointSixFiveNotesDue2022Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointThreeSevenFivePercentNotesDue2050Member2020-01-012020-09-300000318154amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointTwoZeroNotesDue2027Member2020-01-012020-09-300000318154amgn:OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:FourPointFiveZeroPercentNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FloatingRateNotesDue2020Member2020-01-012020-09-300000318154amgn:TwoPointTwoZeroNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember2020-01-012020-09-300000318154amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMemberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154amgn:SixPointFourZeroPercentNotesDue2039Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneFivePercentNotesDue2040Member2020-01-012020-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2020-01-012020-09-300000318154amgn:FourPercentPoundSterlingNotesDue2029Memberus-gaap:NotesPayableToBanksMember2020-01-012020-09-300000318154us-gaap:DebtSecuritiesPayableMembersrt:MinimumMember2020-01-012020-09-300000318154us-gaap:DebtSecuritiesPayableMembersrt:MaximumMember2020-01-012020-09-300000318154amgn:ThreePointFourFivePercentNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-02-290000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointOneZeroPercentNotesDue2021Member2020-02-290000318154amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMemberus-gaap:NotesPayableToBanksMember2020-02-290000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2020-02-012020-02-290000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2020-02-290000318154us-gaap:NotesPayableToBanksMemberus-gaap:InterestExpenseMember2020-02-012020-02-290000318154amgn:FourPointFiveZeroPercentNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-02-290000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember2020-02-290000318154amgn:TwoPointTwoZeroNotesDue2020Memberus-gaap:NotesPayableToBanksMember2020-02-290000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:InterestRateSwapOneMember2020-03-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:InterestRateSwapTwoMember2020-03-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableToBanksMember2020-03-310000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember2020-03-310000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember2020-03-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2022Memberus-gaap:NotesPayableToBanksMember2020-03-310000318154amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableToBanksMember2020-03-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-01-012020-03-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:InterestRateSwapThreeMember2020-03-310000318154amgn:ThreePointFourFivePercentNotesDue2020Memberus-gaap:NotesPayableOtherPayablesMember2020-09-300000318154amgn:ThreePointFourFivePercentNotesDue2020Memberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300000318154amgn:ThreePointFourFivePercentNotesDue2020Memberus-gaap:NotesPayableOtherPayablesMember2019-12-310000318154amgn:ThreePointFourFivePercentNotesDue2020Memberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310000318154us-gaap:NotesPayableOtherPayablesMemberamgn:FourPointOneZeroPercentNotesDue2021Member2020-09-300000318154us-gaap:NotesPayableOtherPayablesMemberamgn:FourPointOneZeroPercentNotesDue2021Memberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300000318154us-gaap:NotesPayableOtherPayablesMemberamgn:FourPointOneZeroPercentNotesDue2021Member2019-12-310000318154us-gaap:NotesPayableOtherPayablesMemberamgn:FourPointOneZeroPercentNotesDue2021Memberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310000318154us-gaap:NotesPayableOtherPayablesMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2020-09-300000318154us-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2020-09-300000318154us-gaap:NotesPayableOtherPayablesMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2019-12-310000318154us-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMemberamgn:ThreePointEightSevenFivePercentNotesDue2021Member2019-12-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2022Memberus-gaap:NotesPayableOtherPayablesMember2020-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2022Memberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2022Memberus-gaap:NotesPayableOtherPayablesMember2019-12-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2022Memberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableOtherPayablesMember2020-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableOtherPayablesMember2019-12-310000318154amgn:ThreePointSixTwoFivePercentNotesDue2024Memberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310000318154amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableOtherPayablesMember2020-09-300000318154amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300000318154amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableOtherPayablesMember2019-12-310000318154amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableOtherPayablesMember2020-09-300000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableOtherPayablesMember2019-12-310000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableOtherPayablesMember2020-09-300000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableOtherPayablesMember2019-12-310000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-12-310000318154us-gaap:NotesPayableOtherPayablesMember2020-09-300000318154us-gaap:NotesPayableOtherPayablesMember2019-12-310000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember2020-01-012020-09-300000318154amgn:SixPointThreeSevenFivePercentNotesDue2037Memberus-gaap:NotesPayableToBanksMember2019-07-012019-09-300000318154amgn:SixPointNineZeroPercentNotesDue2038Memberus-gaap:NotesPayableToBanksMember2019-07-012019-09-300000318154amgn:SixPointFourZeroPercentNotesDue2039Memberus-gaap:NotesPayableToBanksMember2019-07-012019-09-300000318154amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2019-07-012019-09-300000318154amgn:FivePointOneFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2019-07-012019-09-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSixFivePercentNotesDue2042Member2019-07-012019-09-300000318154amgn:FivePointThreeSevenFivePercentNotesDue2043Memberus-gaap:NotesPayableToBanksMember2019-07-012019-09-3000003181542020-09-012020-09-3000003181542020-06-012020-06-3000003181542020-07-012020-07-3100003181542020-03-012020-03-3100003181542019-12-012019-12-310000318154srt:ScenarioForecastMember2020-12-082020-12-080000318154us-gaap:SubsequentEventMember2020-10-012020-10-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2019-12-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-03-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-03-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2020-01-012020-03-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-03-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-03-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2020-03-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2020-04-012020-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-04-012020-06-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-04-012020-06-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2020-04-012020-06-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2020-06-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-07-012020-09-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2020-07-012020-09-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2020-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-07-012019-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-07-012019-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-07-012019-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-07-012020-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-07-012019-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2020-09-300000318154us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2020-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2020-09-300000318154us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2020-09-300000318154amgn:CorporateDebtSecuritiesFinancialMemberus-gaap:FairValueInputsLevel1Member2020-09-300000318154amgn:CorporateDebtSecuritiesFinancialMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154amgn:CorporateDebtSecuritiesFinancialMemberus-gaap:FairValueInputsLevel3Member2020-09-300000318154us-gaap:FairValueInputsLevel1Memberamgn:CorporateDebtSecuritiesIndustrialMember2020-09-300000318154amgn:CorporateDebtSecuritiesIndustrialMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154us-gaap:FairValueInputsLevel3Memberamgn:CorporateDebtSecuritiesIndustrialMember2020-09-300000318154us-gaap:FairValueInputsLevel1Memberamgn:CorporateDebtSecuritiesOtherMember2020-09-300000318154us-gaap:FairValueInputsLevel2Memberamgn:CorporateDebtSecuritiesOtherMember2020-09-300000318154us-gaap:FairValueInputsLevel3Memberamgn:CorporateDebtSecuritiesOtherMember2020-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2020-09-300000318154us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-09-300000318154us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-09-300000318154us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-09-300000318154us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember2020-09-300000318154amgn:OtherShortTermInterestBearingSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154amgn:OtherShortTermInterestBearingSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-09-300000318154us-gaap:FairValueInputsLevel1Member2020-09-300000318154us-gaap:FairValueInputsLevel2Member2020-09-300000318154us-gaap:FairValueInputsLevel3Member2020-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2020-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member2020-09-300000318154us-gaap:ForeignExchangeContractMember2020-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel1Member2020-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel3Member2020-09-300000318154amgn:CrossCurrencySwapContractsMember2020-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2020-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2020-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2020-09-300000318154us-gaap:InterestRateSwapMember2020-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2019-12-310000318154us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2019-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2019-12-310000318154us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2019-12-310000318154amgn:CorporateDebtSecuritiesFinancialMemberus-gaap:FairValueInputsLevel1Member2019-12-310000318154amgn:CorporateDebtSecuritiesFinancialMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154amgn:CorporateDebtSecuritiesFinancialMemberus-gaap:FairValueInputsLevel3Member2019-12-310000318154us-gaap:FairValueInputsLevel1Memberamgn:CorporateDebtSecuritiesIndustrialMember2019-12-310000318154amgn:CorporateDebtSecuritiesIndustrialMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154us-gaap:FairValueInputsLevel3Memberamgn:CorporateDebtSecuritiesIndustrialMember2019-12-310000318154us-gaap:FairValueInputsLevel1Memberamgn:CorporateDebtSecuritiesOtherMember2019-12-310000318154us-gaap:FairValueInputsLevel2Memberamgn:CorporateDebtSecuritiesOtherMember2019-12-310000318154us-gaap:FairValueInputsLevel3Memberamgn:CorporateDebtSecuritiesOtherMember2019-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2019-12-310000318154us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-12-310000318154us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2019-12-310000318154us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2019-12-310000318154us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember2019-12-310000318154amgn:OtherShortTermInterestBearingSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154amgn:OtherShortTermInterestBearingSecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-12-310000318154us-gaap:FairValueInputsLevel1Member2019-12-310000318154us-gaap:FairValueInputsLevel2Member2019-12-310000318154us-gaap:FairValueInputsLevel3Member2019-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2019-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member2019-12-310000318154us-gaap:ForeignExchangeContractMember2019-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel1Member2019-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel3Member2019-12-310000318154amgn:CrossCurrencySwapContractsMember2019-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2019-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2019-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2019-12-310000318154us-gaap:InterestRateSwapMember2019-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMember2019-12-310000318154us-gaap:CashFlowHedgingMemberamgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMemberamgn:CrossCurrencySwapContractsMember2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMemberamgn:CrossCurrencySwapContractsMembercurrency:EUR2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMemberamgn:CrossCurrencySwapContractsMembercurrency:USD2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2020-09-300000318154us-gaap:CashFlowHedgingMembercurrency:CHFamgn:CrossCurrencySwapContractsMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMembercurrency:USDamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberamgn:CrossCurrencySwapContractsMember2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberamgn:CrossCurrencySwapContractsMembercurrency:EUR2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMemberamgn:CrossCurrencySwapContractsMembercurrency:USD2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMembercurrency:GBPamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMembercurrency:USDamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMember2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMembercurrency:GBP2020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMembercurrency:USD2020-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2019-07-012019-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2019-01-012019-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMember2020-07-012020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMember2019-07-012019-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMember2020-01-012020-09-300000318154us-gaap:CashFlowHedgingMemberamgn:CrossCurrencySwapContractsMember2019-01-012019-09-300000318154us-gaap:CashFlowHedgingMember2020-07-012020-09-300000318154us-gaap:CashFlowHedgingMember2019-07-012019-09-300000318154us-gaap:CashFlowHedgingMember2020-01-012020-09-300000318154us-gaap:CashFlowHedgingMember2019-01-012019-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2019-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-01-012020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-01-012020-09-300000318154us-gaap:LongTermDebtMemberamgn:InterestRateSwapAtThenCurrentInterestRatesMember2020-09-300000318154amgn:LongTermDebtCurrentMaturitiesMember2020-09-300000318154amgn:LongTermDebtCurrentMaturitiesMember2019-12-310000318154us-gaap:LongTermDebtMember2020-09-300000318154us-gaap:LongTermDebtMember2019-12-310000318154us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000318154us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000318154us-gaap:InterestRateSwapMember2020-07-012020-09-300000318154us-gaap:InterestRateSwapMember2020-01-012020-09-300000318154us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-07-012019-09-300000318154us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-07-012019-09-300000318154us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberamgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-09-300000318154us-gaap:InterestRateSwapMember2019-07-012019-09-300000318154us-gaap:InterestRateSwapMember2019-01-012019-09-300000318154amgn:ForeignCurrencyAndCrossCurrencySwapsMember2020-09-300000318154us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2020-09-300000318154us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2019-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberamgn:OtherCurrentNoncurrentAssetsMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:CrossCurrencySwapContractsMemberamgn:OtherCurrentNoncurrentAssetsMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:CrossCurrencySwapContractsMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:OtherCurrentNoncurrentAssetsMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMember2020-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2020-09-300000318154us-gaap:NondesignatedMember2020-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberamgn:OtherCurrentNoncurrentAssetsMember2019-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2019-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:CrossCurrencySwapContractsMemberamgn:OtherCurrentNoncurrentAssetsMember2019-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberamgn:CrossCurrencySwapContractsMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2019-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:OtherCurrentNoncurrentAssetsMember2019-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2019-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMember2019-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2019-12-310000318154us-gaap:NondesignatedMember2019-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-37702
Amgen Inc.
(Exact name of registrant as specified in its charter)
Delaware 95-3540776
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
One Amgen Center Drive 91320-1799
Thousand Oaks
California
(Address of principal executive offices) (Zip Code)
(805) 447-1000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.0001 par valueAMGNThe NASDAQ Global Select Market
1.250% Senior Notes Due 2022AMGN22New York Stock Exchange
2.00% Senior Notes Due 2026AMGN26New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filerNon-accelerated filer
Smaller reporting companyEmerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
No 
As of October 23, 2020, the registrant had 582,168,612 shares of common stock, $0.0001 par value, outstanding.



AMGEN INC.
INDEX
  Page No.
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 6.
i


PART I — FINANCIAL INFORMATION 

Item 1.FINANCIAL STATEMENTS
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per-share data)
(Unaudited)

 Three months ended
September 30,
Nine months ended
September 30,
 2020201920202019
Revenues:
Product sales$6,104 $5,463 $17,906 $16,323 
Other revenues319 274 884 842 
Total revenues6,423 5,737 18,790 17,165 
Operating expenses:
Cost of sales
1,561 1,036 4,562 3,103 
Research and development1,062 1,001 2,978 2,804 
Selling, general and administrative1,346 1,223 3,957 3,637 
Other1 1 162 (5)
Total operating expenses3,970 3,261 11,659 9,539 
Operating income2,453 2,476 7,131 7,626 
Interest expense, net302 313 944 988 
Interest and other income, net55 114 69 517 
Income before income taxes2,206 2,277 6,256 7,155 
Provision for income taxes185 309 607 1,016 
Net income$2,021 $1,968 $5,649 $6,139 
Earnings per share:
Basic$3.45 $3.29 $9.61 $10.08 
Diluted$3.43 $3.27 $9.54 $10.01 
Shares used in calculation of earnings per share:
Basic585 599 588 609 
Diluted589 602 592 613 

See accompanying notes.
1


AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)

Three months ended
September 30,
Nine months ended
September 30,
 2020201920202019
Net income$2,021 $1,968 $5,649 $6,139 
Other comprehensive (loss) income, net of reclassification adjustments and taxes:
Gains (losses) on foreign currency translation14 (39)(41)(56)
(Losses) gains on cash flow hedges(128)86 (305)27 
Gains (losses) on available-for-sale securities1 30 (20)404 
Other(7) (9)6 
Other comprehensive (loss) income, net of taxes(120)77 (375)381 
Comprehensive income$1,901 $2,045 $5,274 $6,520 

See accompanying notes.
2


AMGEN INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per-share data)

September 30, 2020December 31, 2019
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$9,087 $6,037 
Marketable securities3,273 2,874 
Trade receivables, net4,094 4,057 
Inventories3,942 3,584 
Other current assets2,265 1,888 
Total current assets22,661 18,440 
Property, plant and equipment, net4,816 4,928 
Intangible assets, net17,254 19,413 
Goodwill14,674 14,703 
Other assets5,232 2,223 
Total assets$64,637 $59,707 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$1,161 $1,371 
Accrued liabilities8,701 8,511 
Current portion of long-term debt91 2,953 
Total current liabilities9,953 12,835 
Long-term debt34,196 26,950 
Long-term deferred tax liabilities210 606 
Long-term tax liabilities7,560 8,037 
Other noncurrent liabilities1,759 1,606 
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 583.5 shares in 2020 and 591.4 shares in 2019
31,713 31,531 
Accumulated deficit(19,851)(21,330)
Accumulated other comprehensive loss(903)(528)
Total stockholders’ equity10,959 9,673 
Total liabilities and stockholders’ equity$64,637 $59,707 

See accompanying notes.
3


AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In millions, except per-share data)
(Unaudited)

Number
of shares
of common
stock
Common
stock and
additional
paid-in capital
Accumulated
deficit
Accumulated
other
comprehensive
loss
Total
Balance as of December 31, 2019591.4 $31,531 $(21,330)$(528)$9,673 
Cumulative effect of changes in accounting principles, net of tax
— — (2)— (2)
Net income— — 1,825 — 1,825 
Other comprehensive loss, net of taxes
— — — (134)(134)
Dividends declared on common stock ($1.60 per share)
— — (938)— (938)
Issuance of common stock in connection with the Company’s equity award programs
0.9 10 — — 10 
Stock-based compensation expense— 52 — — 52 
Tax impact related to employee stock-based compensation expense
— (68)— — (68)
Repurchases of common stock(4.3)— (933)— (933)
Balance as of March 31, 2020588.0 31,525 (21,378)(662)9,485 
Net income— — 1,803 — 1,803 
Other comprehensive loss, net of taxes— — — (121)(121)
Issuance of common stock in connection with the Company’s equity award programs
1.0 65 — — 65 
Stock-based compensation expense— 101 — — 101 
Tax impact related to employee stock-based compensation expense
— (81)— — (81)
Repurchases of common stock(2.6)— (591)— (591)
Other— — (2)— (2)
Balance as of June 30, 2020586.4 31,610 (20,168)(783)10,659 
Net income— — 2,021 — 2,021 
Other comprehensive loss, net of taxes— — — (120)(120)
Dividends declared on common stock ($1.60 per share)
— — (952)— (952)
Issuance of common stock in connection with the Company’s equity award programs
0.1 5 — — 5 
Stock-based compensation expense— 109 — — 109 
Tax impact related to employee stock-based compensation expense
— (11)— — (11)
Repurchases of common stock(3.0)— (752)— (752)
Balance as of September 30, 2020583.5 $31,713 $(19,851)$(903)$10,959 

See accompanying notes.



4


AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In millions, except per-share data)
(Unaudited)

Number
of shares
of common
stock
Common
stock and
additional
paid-in capital
Accumulated
deficit
Accumulated
other
comprehensive
loss
Total
Balance as of December 31, 2018629.6 $31,246 $(17,977)$(769)$12,500 
Net income— — 1,992 — 1,992 
Other comprehensive income, net of taxes
— — — 253 253 
Dividends declared on common stock ($1.45 per share)
— — (879)— (879)
Issuance of common stock in connection with the Company’s equity award programs
0.7 6 — — 6 
Stock-based compensation expense— 64 — — 64 
Tax impact related to employee stock-based compensation expense
— (73)— — (73)
Repurchases of common stock(15.9)— (3,031)— (3,031)
Balance as of March 31, 2019614.4 31,243 (19,895)(516)10,832 
Net income— — 2,179 — 2,179 
Other comprehensive income, net of taxes— — — 51 51 
Issuance of common stock in connection with the Company’s equity award programs
0.8 23 — — 23 
Stock-based compensation expense— 97 — — 97 
Tax impact related to employee stock-based compensation expense
— (50)— — (50)
Repurchases of common stock(13.1)— (2,349)— (2,349)
Other— — 11 — 11 
Balance as of June 30, 2019602.1 31,313 (20,054)(465)10,794 
Net income— — 1,968 — 1,968 
Other comprehensive income, net of taxes
— — — 77 77 
Dividends declared on common stock ($1.45 per share)
— — (880)— (880)
Issuance of common stock in connection with the Company’s equity award programs
0.3 37 — — 37 
Stock-based compensation expense— 108 — — 108 
Tax impact related to employee stock-based compensation expense
— (7)— — (7)
Repurchases of common stock(6.2)— (1,170)— (1,170)
Balance as of September 30, 2019596.2 $31,451 $(20,136)$(388)$10,927 

See accompanying notes.

5


AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)

 Nine months ended
September 30,
 20202019
Cash flows from operating activities:
Net income$5,649 $6,139 
Depreciation, amortization and other2,728 1,504 
Deferred income taxes(339)(172)
Other items, net270 169 
Changes in operating assets and liabilities, net of acquisition:
Trade receivables, net(31)(63)
Inventories(316)(101)
Other assets64 (269)
Accounts payable(202)(196)
Accrued income taxes, net(301)(128)
Long-term tax liabilities110 (262)
Other liabilities712 15 
Net cash provided by operating activities8,344 6,636 
Cash flows from investing activities:
Purchases of marketable securities(5,329)(9,062)
Proceeds from sales of marketable securities2,597 3,019 
Proceeds from maturities of marketable securities2,338 18,441 
Purchases of property, plant and equipment(435)(430)
Purchases of equity method investments(3,154)(14)
Other(34)(282)
Net cash (used in) provided by investing activities(4,017)11,672 
Cash flows from financing activities:
Net proceeds from issuance of debt8,914  
Repayment of debt(5,000)(4,514)
Repurchases of common stock(2,281)(6,608)
Dividends paid(2,823)(2,649)
Other(87)(67)
Net cash used in financing activities(1,277)(13,838)
Increase in cash and cash equivalents3,050 4,470 
Cash and cash equivalents at beginning of period6,037 6,945 
Cash and cash equivalents at end of period$9,087 $11,415 

See accompanying notes.
6


AMGEN INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2020
(Unaudited)

1. Summary of significant accounting policies
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation
The financial information for the three and nine months ended September 30, 2020 and 2019, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020.
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.8 billion and $8.4 billion as of September 30, 2020 and December 31, 2019, respectively.
Equity method investments
The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income.
We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.
7


Recent accounting pronouncements
In June 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets are now presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the former other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements.
In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity may change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.
8


2. Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of rest-of-world (ROW) revenues relates to products sold in Europe.
Revenues were as follows (in millions):
Three months ended September 30,
20202019
U.S.ROWTotalU.S.ROWTotal
Enbrel® (etanercept)
$1,289 $36 $1,325 $1,323 $43 $1,366 
Prolia® (denosumab)
478 223 701 425 205 630 
Neulasta® (pegfilgrastim)
484 71 555 619 92 711 
Otezla® (apremilast)
439 99 538    
XGEVA® (denosumab)
363 118 481 356 120 476 
Aranesp® (darbepoetin alfa)
158 226 384 204 248 452 
KYPROLIS® (carfilzomib)
173 87 260 163 103 266 
Repatha® (evolocumab)
92 113 205 85 83 168 
Other products1,142 513 1,655 854 540 1,394 
Total product sales(1)
$4,618 $1,486 6,104 $4,029 $1,434 5,463 
Other revenues319 274 
Total revenues$6,423 $5,737 

Nine months ended September 30,
20202019
U.S.ROWTotalU.S.ROWTotal
ENBREL$3,619 $105 $3,724 $3,744 $136 $3,880 
Prolia®
1,341 673 2,014 1,273 647 1,920 
Neulasta®
1,538 219 1,757 2,231 325 2,556 
Otezla®
1,280 298 1,578    
XGEVA®
1,036 361 1,397 1,091 355 1,446 
Aranesp®
489 704 1,193 578 724 1,302 
KYPROLIS®
527 266 793 483 295 778 
Repatha®
331 303 634 259 202 461 
Other products3,164 1,652 4,816 2,503 1,477 3,980 
Total product sales(1)
$13,325 $4,581 17,906 $12,162 $4,161 16,323 
Other revenues884 842